Trial Profile
An open-label extension study to assess long term safety and tolerability of omalizumab treatment in adults and adolescents with severe allergic asthma who participated in the 52 week CIGE250011E2 study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Nov 2014
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Allergic asthma
- Focus Adverse reactions
- Sponsors Novartis
- 24 Oct 2011 Planned end date changed to 1 Jun 2006 as reported by ClinicalTrials.gov as reported by ClinicalTrials.gov.
- 01 Aug 2007 New trial record.